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Abstract
The activation of seven-transmembrane receptors (7TMRs) allows cells to sense their environment
and convert extracellular signals (like hormone binding) into intracellular signals (through G
protein-coupled and/or β arrestin-coupled pathways). A single 7TMR is capable of transducing a
wide spectrum of physiological responses inside a cell by coupling to these pathways. This
intracellular pleiotropic action is enabled by multiple conformations exhibited by these receptors.
Developments in membrane protein structure determination technologies have led to a rapid
increase in crystal structures for many 7TMRs. Majority of these receptors have been crystallized
in their inactive conformation and, for some, one of the many active conformations has also been
crystallized. Given the topological constraints of a lipid bilayer that results in a single fold of
seven almost parallel TM helices connected by mostly unstructured loops, these structures exhibit
a diversity of conformations not only across the receptors but also across the different functional
forms for receptors with structures for one of the functionally active conformations. Here we
present a method to characterize this conformational diversity in terms of TransMembrane Helix
TOPology (TMHTOP) parameters (TMHTOP) and how to use these helix orientation parameters
to predict functionally-distinct multiple conformations for these receptors. The TMHTOP
parameters enable a quantification of the structural changes that underlie 7TM activation and also
sheds a unique mechanistic light on the pleiotropic nature of these receptors. It provides a common
language to describe the 7TMR activation mechanisms as well as differences across many
receptors in terms of visually intuitive structural parameters. Protein structure prediction methods
can use these parameters to describe 7TMR conformational ensembles, which coupled to
experimental data can be used to develop testable hypotheses for the structural basis of 7TMR
functions.
Keywords
G protein-coupled receptors; GPCRs; Conformational ensemble; Functional selectivity; Protein
structure prediction; Transmembrane Helix Topology
© 2011 Elsevier Inc. All rights reserved.
*Corresponding author; abrol@wag.caltech.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Methods. Author manuscript; available in PMC 2012 December 17.
Published in final edited form as:
Methods. 2011 December ; 55(4): 405–414. doi:10.1016/j.ymeth.2011.12.005.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
1. Introduction
The seven-transmembrane receptors (7TMRs) are integral membrane proteins that form the
largest superfamily in the human genome with ~800 receptors identified, including ~370
non-sensory receptors organized in 5 families (GRAFS): Glutamate, Rhodopsin, Adhesion,
Frizzled/Taste2, and Secretin [1, 2]. A variety of bioactive molecules, including biogenic
amines, peptides, and hormones modulate the activity of 7TMRs to effect regulation of
essential physiological processes (e.g. neurotransmission, cellular metabolism, secretion,
cell growth, immune defense, and differentiation) through G protein-coupled and/or β
arrestin-coupled pathways [3]. The coupling to G proteins is the origin of 7TMRs being
commonly referred to as GPCRs (G protein-coupled receptors). A structural understanding
of their function will have a tremendous and broad impact, asthe dysregulation of these
receptors often plays an important role in disease pathologies [2, 4].
The pleiotropic nature of these receptors in response to different extracellular signals is the
result of different ensembles of protein conformations that are stabilized in apo-wild-type,
apo-mutant, and ligand-bound forms, leading to different functional states of the receptors
[3]. The current structural, thermodynamic, and functional knowledge of 7TMRs suggests
an emerging conformational-ensemble picture like one shown in Fig. 1, which provides a
schematic of lowest energy 7TMR conformations in different scenarios. “I” refers to the
most stable (lowest energy) inactive conformation for a receptor. “C” refers to the
conformations besides the “I” conformation that are thermally accessible for constitutively
active receptors. “G” refers to conformations that can exclusively couple to G proteins. “β”
refers to conformations that can exclusively couple to β arrestins and “G/β” refers to
conformations that can couple to G proteins as well as β arrestins. This figure will look
different for different receptors and is drawn to provide a conceptual “conformational
ensemble” framework to think about 7TMRs and what can potentially happen to their
ensembles in mutant forms and/or in the presence of different ligands. It would be
impractical to list all the possibilities. This figure suggests that it is possible to stabilize
functionally different conformations, e.g., in the presence of an agonist B plus G protein (6th
column in Fig. 1), a “G” conformation (active) may be stabilized (as observed for β2
adrenergic receptor bound to Gs or Gs-mimic[5, 6]), whereas an agonist A by itself (4th
column in Fig. 1) may still stabilize the inactive conformation (as observed for the β2
adrenergic receptor bound to an agonist [7]) and in the presence of an agonist A, the mutant
Y of the receptor (7th column in Fig. 1) may stabilize a “β” conformation (that exclusively
couples to β arrestins). This is inherently complex, but it does promise the possibility of a
specific ligand or mutant or ligand-mutant combination stabilizing a conformation that may
be responsible for a specific function. Thus, a full structural insight into the pleiotropic
function of 7TMRs will require the functional characterization of their multiple
conformations to highlight how different ligands or mutations modulate (stabilize and/or
induce) conformations to cause their effects [3, 8–11]. To complement these functional
studies, any protein modeling approach for 7TMRs should be able to predict these
ensembles of protein conformations and how they evolve in the presence of ligands and
mutations.
This also has profound implications for the ability to control receptor pharmacology. The
lack of experimental structures for most human 7TMRs (none were available until 2007) has
led to the use of high-throughput screening (HTS) and virtual ligand screening (VLS)
techniques in drug design, which do not require protein structures. A large proportion (43%)
of drug candidates in clinical trials fail due to lack of efficacy, toxicity and side-effects [12].
Some side effects result from drugs binding to other 7TMRs or other subtypes of the same
receptor (e.g., pramipexole which is used to treat Parkinson’s disease [as a dopamine D2
receptor agonist] can produce behavioral side-effects such as compulsive gambling
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associated with dopamine D3 receptor) [13]. Such side effects might be minimized by
designing D2 selective agonists, which requires atomic-level structures for both D2 and D3
receptors. Some side effects are caused by the target receptor when ligand activates both
beneficial and undesirable signaling pathways. An example is the niacin receptor GPR109A.
Niacin is therapeutically beneficial as an antilypolytic agent (via G protein mediated
pathways), but also causes cutaneous flushing which has been directly linked to the
activation of β arrestin 1 pathways [14]. An analog of this molecule will be highly desirable
that doesn’t affect the G protein pathways but destabilizes the coupling to β arrestin 1 and
blocks that pathway. This picture states that different ligands (and mutants) can stabilize
different 7TMR conformations by changing its wild-type energy landscape, which can be
further modulated by the presence of G proteins or β arrestins. Such detailed understanding
of the effects of a drug candidate on different signaling pathways can assist in designing
drugs with minimal on-target side effects, which in turn requires a structural understanding
of the different conformations that may be coupling to different pathways.
The concepts in Fig. 1 also promise that an understanding of how these structural ensembles
change can, in principle, allow us to stabilize multiple functionally-distinct conformations to
the point of being crystallizable. In the last few years there has been a rapid increase in the
solution of crystal structures for many 7TMRs[5, 7, 15–25] due mainly to a technological
revolution in membrane protein structure determination methods [26]. Crystal structures
corresponding to inactive forms are now available for the β2 adrenergic [16], A2A adenosine
[17], D3 dopamine [21], CXCR4 chemokine [22], and H1 histamine receptors in humans.
Inactive structures are also available for bovine rhodopsin [15, 23], turkey β1[18], and squid
rhodopsin [19, 25] receptors. The structures of bovine opsin with/without a Gα peptide [20,
24], bovine metarhodopsin II [27], agonist-bound human β2 adrenergic receptor stabilized
by a G-protein-mimicking nanobody [5] or very recently by the Gs heterotrimer [6], and
agonist bound adenosine A2A receptor [28] are the first set of structures to provide a direct
glimpse of one or more of the “active” states of those receptors. The topological comparison
of many of these crystal structures and their implications for 7TMR activation has been
reviewed extensively [29–33]. Structure determination efforts are moving towards the
stabilization of 7TMRs in different functional conformations (e.g., bound to agonists, G
proteins or β arrestins), and structural computational biology can help by mapping the
energy landscape sampled by 7TMRs during their life-cycle and characterizing the critical
conformations along the way to link with those that are observed in experimental structures
to develop testable hypotheses for their structure-function relationships. A characterization
of the above mentioned structural diversity of 7TMR conformational ensembles in terms of
a few intuitive parameters can help in analyzing the experimental structures and also assist
in the modeling of these receptors in different functional forms, allowing protein structure
prediction and modeling to play an increasingly important role in providing detailed
structural information about 7TMR activation and ligand binding.
Membrane proteins have been the focus of structure prediction and dynamics simulations for
some years [34]. The interaction of these proteins with their lipid environment is critical for
folding and studies have attempted to quantify this interaction on an absolute
thermodynamic basis [35] by providing thermodynamic costs for the insertion of TM helical
amino acids into the lipid bilayer [36]. The three-dimensional structure of these α-helical
membrane proteins is also affected by interhelical interactions (H-bonds and salt-bridges)
[35]. An accurate structure prediction methodology needs to be able to sample and describe
these interhelical interactions thoroughly.
Many methods have been used to obtain model structures for membrane proteins. These
methods have been reviewed elsewhere [37, 38]. For 7TMRs the main approach has been
homology modeling and most studies have used constraints based on mutation and binding
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experiments coupled to the homologous rhodopsin structure to guide additional mutation
experiments. This approach has not been sufficiently accurate for predicting binding sites of
ligands [39]. Our group has been developing de novo computational approaches (not
homology-based) for predicting the structures of 7TMRs and their ligand binding sites. We
have been successful in predicting 7TMR structures (mostly inactive, some active) validated
by known mutation and ligand SAR data [40–49], as reviewed here [50]. These approaches
sampled receptor conformations using only TM helix rotation angles, which (we have
found) is inadequate to predict structures for 7TMRs distant (in sequence space) from a
template or to predict multiple conformations for a given 7TMR.
To address this we have developed a method to characterize any 7TMR helix bundle
conformation in terms of relative orientation describing TMHTOP parameters for all seven
TM helices. This analysis method allows for the comparison of any 7TMR conformation
against any other 7TMR conformation. This characterization of differences across all known
templates (all 7TMR crystal conformations and validated predicted conformations), when
correlated with sequence identity (or similarity), provides information vital for protein
modeling efforts to assess the conformational space sampling that may be necessary in
starting from any template. This comparison done between inactive and active
conformations (that have been obtained for some 7TMRs) can provide mechanistic insight
into activation in terms of the helix degrees of freedom (DOFs) that vary the most during
activation. This method ignores the loops to characterize the 7TMRs for two reasons. First,
secondary structure (helices or sheets) is present only in part of the loops making it difficult
to define simple orientation parameters for them. Second, the positioning of loops above and
below the lipid bilayer is governed by the orientations and lengths of TM helices connected
to them making it difficult to characterize their orientation with respect to the membrane
middle plane.
In the next section we will describe the method to characterize the orientation of any 7TMR
conformation and then correlate the orientation parameters with the sequence-based
measures like identity or similarity. These correlations provide valuable insight into the
conformational diversity across different 7TMRs and how these parameters can be used in
protein structure prediction workflows aimed at 7TMRs. We have used these orientation
parameters to develop and test rigorous conformational sampling methods to provide an
ensemble of thermally accessible apo and holo conformations, corresponding to different
functional states of the receptor. To this effect we have developed a method called
GEnSeMBLE (GPCR Ensemble of Structures in the Membrane BiLayer Environment) that
uses these orientation parameters to sample TM helix bundle conformations and predict low
energy conformations for man 7TMRs (see, for example, ref. [46]). Some results of the
application of this method will be highlighted to show the usefulness of the orientation
parameters.
2. Methods
The seven TM helix topology of 7TMRs presents unique advantages and challenges for the
quantification of sequence-structure relationships. Many comparative modeling programs
can predict structures of globular proteins (with 30% or higher sequence identity to a
crystallized protein) to a reasonable accuracy, as the belief is that a major fraction of
structural folds are now known for globular proteins. Same cannot be said for membrane
proteins in general. 7TMRs, however, can be thought of having one structural fold that
crosses the membrane bilayer seven times in the form of seven TM helices interconnected
by intracellular and extracellular loops. In spite of the boundary conditions imposed the
membrane and lengths of loops, these seven helices can be packed together in innumerable
ways. We will describe below how to quantify the topology of these TM helix packings in
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absolute terms using TMHTOP orientation parameters describing each of the seven TM
helices, which can be used to characterize different receptor structures or different
conformations of the same receptor.
2.1 TM Helix Orientation Coordinate System
To quantify the relationship between sequence and structure for 7TMRs, we need to
characterize the known structures using some standard geometrical parameters. As crystal
structures don’t provide absolute membrane orientation of 7TMRs, we use the OPM
(Orientation of Proteins in Membrane, [51]) database, which aligns each newly deposited
membrane protein structure to an implicit membrane maximizing the free energy of
insertion of the membrane protein into the membrane. The middle of the membrane
corresponds to the z=0 plane, which we designate asthe hydrophobic plane. Each 7TMR
structure can then be characterized by the six orientation parameters of the seven helices as
defined in Fig. 2, which shows how the helix position and orientation are defined in the
frame of this z=0 hydrophobic plane.
Helix position (R) on the hydrophobic plane is defined by the first two coordinates x and y.
Third parameter h corresponds to the hydrophobic center (HPC) residue from the helix that
will be positioned on the (z=0) hydrophobic plane. In practice, this hydrophobic center
residue is a non-integer to signify that the positioning of a TM helix in the z=0 plane could
lie between two residues. Fourth parameter is the angle θ that refers to the helix tilt angle
signifying how much a helix tilts with respect to the z-axis or the membrane normal. This
angle can be directly associated with determining the hydrophobic match of the helix with
the membrane bilayer. Fifth parameter is the angle ϕ, called the helix sweep angle, which
signifies the azimuthal angle of the helix for a fixed value of the helix tilt angle θ. So, the
sweep angle ϕ (for a fixed θ) samples a helix degree of freedom (DOF) that preserves the
hydrophobic match with the membrane. The last orientation parameter is the helix rotation
angle η which corresponds to the helix rotation angle about its (as yet undefined) axis. This
angle requires the specification of an η residue (ηRES) which is used as a reference to define
this rotation angle uniquely. For class A 7TMRs, this residue is chosen to be the most
conserved residue in each helix (given by Ballesteros numbering scheme X.50[52]) where X
is the TM helix in question. The exception to this is TM helix 3, for which the residue
position 3.32 is used as ηRES because residue position 3.50 is located at the bottom of this
helix, which may not provide a consistent η rotation angle representing the whole helix. The
helix DOF controlled by this rotation angle most directly controls which face of a specific
helix may be interacting with another helix in the TM bundle.
The helixtilt angle θ, sweep angle ϕ, and rotation angle η require a unique definition of the
helical axis which needs to account for the reality of bent helices found in integral
membrane proteins, as Proline residues are commonly found in their TM helices. We use a
helical axis that corresponds to the least moment of inertia vector obtained by the
eigensolution of the moment of inertia matrix for the helix using only heavy backbone
atoms. We rotate the membrane-aligned 7TMRs from the OPM database in the x-y plane
such that the helical axis of TM helix 3 goes through the origin, and that of TM helix 2
intersects the x-axis. This transformation coupled to the convention that extracellular face of
the receptor points in the +z direction results in a unique orientation reference frame for
7TMRs, which will allow for a consistent and quantitative comparison of the helix
orientation parameters across different receptors or across different conformations of the
same receptor. As an example, Table 1 shows the six TM helix orientation parameters for
the first crystallized human β2 adrenergic receptor structure [16]. It also lists the ηRES used
to define the helix rotation angle η for each TM helix.
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2.2 TM Helix Orientation Parameters for Inactive 7TMR Conformations
The TMHTOP helix orientation parameters for all seven helices in a 7TMR provide a
quantitative view of its topology in the membrane and can be directly compared against
another receptor to quantify topological deviations across receptors. Of the six orientation
parameters, five parameters (x,y,θ, ϕ, η) can be directly compared across different receptors
to capture the topological diversity. The sixth parameter h specifies the hydrophobic
residues aligned on the membrane middle plane and is less insightful in capturing 7TM helix
bundle differences. Furthermore, we reduce the helix position parameters x,y into a single
parameter R that captures the distance from origin of the point of intersection of the helical
axis and the hydrophobic plane. So, the deviation of this distance from origin between two
7TMRs i and j for a TM helix k is given by:
(1)
The corresponding deviation of the helix orientation angles is given by:
(2)
This analysis has been applied to inactive conformations of 7TMRs that have been
crystallized so far, which is expected to provide useful insight into the topological diversity
across these different 7TMRs. The inactive conformations used in this comparison are the
following: bovRhod (pdbid: 1u19 [23]), humBeta2 (pdbid: 2rh1 [16]), turBeta1 (pdbid: 2vt4,
chainB [18]), humA2A (pdbid: 3eml[17]), squRhod (pdbid: 2z73[19]), humD3 (pdbid:
3pbl[21]), humCXCR4 (pdbid: 3odu[22]), and humH1 (pdbid: 3rze[53]). All conformations
were pre-aligned to humBeta2 OPM conformation (2rh1) to capture absolute differences
across conformations and to reduce the potential for noise coming from different OPM
orientations.
The panels in Figure 3 attempt to capture the topological differences across this set of
inactive receptor conformations. Figure 3A shows the deviations in helix position (ΔR) as a
function of the corresponding deviations in helix rotation angle (Δη) across all eight inactive
receptor conformations in green and across the four aminergic receptors’ (humBeta2,
turBeta1, humD3, and humH1) conformations in red. Each deviation point in Figure 3 is
marked by the TM helix number that it corresponds to, so the panels contain a lot of
information. Figures 3B and 3C show the deviations in helix tilt angle (Δθ) and helix sweep
angle (Δϕ) respectively as a function of the corresponding deviations in helix rotation angle
(Δη). Figures 3D and 3E show the deviations in helix position (ΔR) and helix tilt angle (Δθ)
respectively as a function of the corresponding deviations in helix sweep angle (Δϕ). Figure
3F shows the deviations in helix position (ΔR) as a function of the corresponding deviations
in helix tilt angle (Δθ). So, all pairwise correlations of these deviations are represented in
Figure 3. The deviations across aminergic receptors (shown in red points) are smaller than
those across all eight receptors as expected. Based on Figures 3A, 3D, and 3F, TM5 shows
the biggest deviation in its position ΔR (upto 6Å) across the eight receptors, whereas it is
TM1 that shows the biggest deviation in its position (upto about 4Å) across the aminergic
receptors. Figures 3B, 3E, and 3F show that TM6 displays biggest deviation in its tilt angle
(Δθ) across aminergic as well as all receptors, with deviation among aminergic receptors
(upto 5°) significantly smaller than that among all receptors (upto 15°). Figures 3C, 3D, and
3E show that TM4 and TM6 display the biggest deviations in their helix sweep angles (Δϕ)
for both sets of receptors (upto about 80°). Figures 3A, 3B, and 3C show that TM2 and TM5
display the biggest deviations in their helix rotation angles (Δη) among all receptors (upto
60°), whereas it is TM6 that shows the biggest variability among aminergic receptors (upto
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30°). Overall, this analysis suggests that inactive 7TMR conformations exihibit large
topological diversity, which will be difficult to capture by homology modeling. Even
aminergic receptors display non-negligible topological differences, some of which might be
important for capturing the properties associated with their inactive conformations like
binding to different antagonists and inverse agonists.
2.3 TM Helix Orientation Parameters for Active 7TMR Conformations
The analysis described in the previous section has also been applied to the active
conformations of 7TMRs that have been captured recently in some crystal structures. The
topologies of these active conformations have also been compared to the inactive
conformations analyzed earlier. Three 7TMRs have been crystallized so far in multiple
functionally distinct conformations: Bovine Rhodopsin, Human β2 Adrenergic Receptor,
and Human Adenosine A2A Receptor. This limited number of available active
conformations is not enough to make conclusions about GPCR activation mechanisms, but
the following analysis provides an introduction to the type of analysis enabled by TMHTOP
orientation parameters.
For Bovine Rhodopsin, the following active conformations were compared to the inactive
1U19 (pdbid) conformation [23] and to each other: bovine Opsin (pdbid: 3cap [20]),
rhodopsin mutant E113Q with Gα C-terminal peptide (pdbid: 2×72 [54]), and
metarhodopsin II (pdbid: 3pqr [27]). For Human β2 Adrenergic Receptor, the following
active and inactive conformations were compared to the inactive 2rh1 (pdbid) conformation
[16] and to each other: humBeta2 bound to an inverse agonist (pdbid: 3d4s [55]), humBeta2
bound to inverse agonists and a neutral antagonist (pdbids: 3nya, 3ny8, 3ny9 [56]),
humBeta2 bound to an irreversible agonist (pdbid: 3pds [7]), humBeta2 bound to an agonist
along with a nanobody (pdbid: 3p0g [5]), and humBeta2 bound to the Gs protein
heterotrimer (pdbid: 3sn6[6]). For Human Adenosine A2A Receptor, the following active
conformations were compared to the inactive 3eml (pdbid) conformation [17] and to each
other: humA2A bound to agonist UK432097 (pdbid: 3qak [28]), humA2A bound to agonist
adenosine (pdbid: 2ydo [57]), and humA2A bound to agonist NECA (pdbid: 2ydv [57]). In
all cases, the different conformations were pre-aligned to the corresponding reference
inactive conformation from the OPM database, which was 1u19 for bovRhod, 2rh1 for
humBeta2 and 3eml for humA2A. The results are shown in Figure 4, with rhodopsin
comparisons in blue, β2 comparisons in green and A2A comparisons in red.
Comparisons of active Rhodopsin conformations to the inactive conformation (blue points in
Figure 4) show biggest movements for TM2, TM5 and TM6. The position (R) of TM2
moves the most (~5–6Å), followed by TM5 and TM6 (~3–4Å). Deviations in helix tilt angle
(Δθ) stay below 5° for all TMs. TM6 shows the biggest deviations in helix sweep angle (Δϕ
~ 45°). TM6 also shows the biggest deviations in helix rotation angle (Δη ~ 40°), followed
by TM3 which shows a rotation of about 30°. Comparisons of β2 conformations (green
points in Figure 4) show TM5, TM6 and TM7 with most deviations. TM position doesn’t
deviate by more than 2.5Å (TM7). TM5 shows the largest helix title angle deviation (Δθ ~
5°). TM6 shows the biggest deviation in helix sweep angle (Δϕ ~ 80°) followed by TM4
(~40°). Helix rotation angle deviation (Δη) stays below 20° for all TMs. In the comparison
of active A2A conformations to the inactive one (red points in Figure 4), TM6 and TM7
stand out with the largest deviations. TM6 shows large deviation in helix sweep angle (Δϕ ~
80°) like in β2. TM7 shows a small deviation in helix position (ΔR~2Å) but a large
deviation in helix rotation angle (Δη ~ 75°). The deviations in β2 and A2A conformations
behave differently from those in rhodopsin as noticed clearly in Figure 4C, which shows that
helix sweep angle (ϕ) and helix rotation angle (η) deviations for TM6 are not coupled for β2
and A2A conformations, but they are for rhodopsin.
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The analysis shown in Figure 4 provides topological fingerprints for active conformations
which can be coupled to known function from biochemical experiments. This coupling can
allow one to hypothesize about the function of any observed topologies. Different
topological fingerprints would invariably be associated with some type of different
downstream functional outcome, but same fingerprints may not always lead to same
function. An example is the observation of “islands” of points in Figure 4 of identical TMs
for a given receptor. Since these “islands” correspond to multiple active conformations that
have been crystallized, they show that those active conformations have very similar TM
helix topologies, e.g. blue points in Figure 4 (for rhodopsin) show islands of TM2, TM5 and
TM6 deviations. These islands capture deviations of opsin, for example, as well as metaII
from the dark state of rhodopsin, suggesting that opsin and metaII have very similar TM
helix topologies. So, their known functional differences could be most likely ascribed to
potential differences in their intracellular loops and/or their C-termini.
Figure 5 shows a minimal version of Figure 4, where only a single inactive-to-active
comparison is included per receptor using the following conformations. For rhodopsin, the
blue points in Figure 5 compare the dark state (pdbid: 1u19 [23]) with the metaII state
(pdbid: 3pqr [27]). For β2, the green points in Figure 5 compare the inactive conformation
bound to carazolol (pdbid: 2rh1 [16]) with the recently crystallized “active” conformation
bound to the full heterotrimeric Gs protein (pdbid: 3sn6 [58]). For A2A, the red points in
Figure 5 compare its inactive conformation bound to antagonist ZM241385 (pdbid: 3eml
[17]) with the recently crystallized active conformation bound to the agonist UK432097
(pdbid: 3qak [28]). Data from this figure shows that as a consensus TM6 appears to be the
most critical TM helix that moves during activation and its consensus motion occurs in the
helix sweep angle (ϕ) space. This motion appears to be the only common denominator based
on the three receptors with experimental active conformations. The differences across these
receptors in terms of structural changes during activation might be specific to sub families of
receptors more closely related to these receptors.
These analyses highlight the fact that the TMHTOP TM helix orientation parameters
provide a standard way to quantify differences across various receptors and across different
conformations of the same receptor, which in turn enables the generation of testable
hypotheses about mechanistic insights into the function in these receptors.
Next, we will compare the differences in these orientation parameters across the receptors
with their sequence identity and similarity, to provide a metric for the reliability of
homology-based models vs de novo structures.
2.4 Sequence vs Topology
The TM regions display high sequence conservation when compared to the loop regions as
is expected (see Table 2). The table shows an all-to-all comparison of the sequence identity
(Table 2A) and sequence similarity (Table 2B) across all eight 7TM receptors that have been
crystallized so far in one or more conformations (bovRhod: bovine Rhodopsin; humBeta2:
human β2 adrenergic receptor; turBeta1: turkey β1 adrenergic receptor; humA2A: human
Adenosine A2A receptor; squRhod: squid Rhodopsin; humD3: human Dopamine D3
receptor; humCXCR4: human Chemokine CXCR4 receptor; humH1: human histamine H1
receptor). Similarity is defined by using the BLOSUM62 matrix[59], where two residues are
considered similar if the corresponding substitution element in the BLOSUM62 matrix is
greater than zero. For each pair of sequences, two numbers are provided in Table 2 for
identity and two for similarity in the form M/N, where M corresponds to identity (or
similarity) for the full sequences and N corresponds to identity (or similarity) for the TM
helix portions of the sequences. The TM helix portions were inferred from the HELIX fields
in the corresponding PDB files of the receptors’ inactive conformations. For each 7TM
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receptor column in Table 2, the receptors with highest and lowest TM region measure
(identity or similarity) to that 7TM receptor are highlighted with green and red cells
respectively. For example, humBeta2 column in Table 2A shows that in terms of TM region
sequence identity, it is closest to turBeta1 and farthest from bovRhod. A curious observation
from Table 2B is that turBeta1 is closest to five out of seven sequences, whereas bovRhod
and humCXCR4 are farthest from four out of seven sequences. Another useful observation
from Table 2B is that aminergic receptors (humBeta2, turBeta1, humD3, and humH1) are all
above 60% similarity of each other in the TM regions.
This comparison when done for a new 7TM receptor (which may be a structure prediction
target) with sequences of known experimental structures provides first hints of good
structural templates to use for the application of protein structure prediction methodologies,
be they de novo methods or homology based methods. One may expect conservatively that
the homology based methods have a good chance of working at least across aminergic
receptors. We will use an example later to compare homology-based and de novo predicted
structures using two templates to suggest a criteria to choose homology-based or de novo
based methods for reliable structure prediction of 7TMRs.
In order to correlate the sequence variability of the crystallized 7TMRs with their TM helix
geometries, we analyzed all-to-all (across these 7TMR systems) maximum absolute
deviations in helix position R, and helix orientation angles θ, ϕ, η over all helices against the
corresponding sequence identity and similarity. The maximum absolute deviations are
defined between a 7TMRi and another 7TMRj by:
(3)
(4)
The index k is for the 7 TM helices. Figure 6 shows this maximum all-to-all deviation (for
all i-j pairs of 7TMRs) as a function of identity or similarity between 7TMRi and 7TMRj, to
highlight the maximum variability seen in these eight systems for any TM helix and to find
correlation to the sequence homology.
Table 3 shows two different correlation coefficients to quantify these correlations. All
coefficients show an inverse correlation because one expects largest deviations for the least
similar receptors. The deviation in TM helix tilt angle (θ) shows the least correlation to
sequence homology, be it TM sequence identity or similarity. This is not surprising because
this angle is strongly influenced by hydrophobic matching with the membrane in addition to
interhelical interactions. The deviation in TM helix rotation angle (η) shows the highest
correlation with sequence homology. This angle has the strongest influence on interhelical
interactions as opposed to the other two angles, so it can be expected that this angle shows
the strongest correlation to TM sequence similarity or identity.
2.5 Homology vs de novo methods for structure prediction of 7TMRs
As Table 1 showed, the eight receptor sequences analyzed above cover a broad sequence
space in class A 7TMRs with sequence identity ranging from 69% down to 19%, and
sequence similarity ranging from 83% down to 35%. Now, given a receptor with unknown
structure, which of the eight receptor sequences provides the ideal template for its homology
modeling or as a reasonable starting structure for its de novo structure prediction? Using the
sequence homology information for this target receptor against the eight available template
sequences, Figure 6 allows one to quantify the conformational space sampling necessary
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within any structure prediction protocol. This comparison of observed changes in TMHTOP
orientation parameters with sequence similarity allows one to estimate changes that might be
expected in similar situations. These estimations are only going to improve as more 7TMR
conformations are observed experimentally. This has strong implications for the structure
prediction of 7TMRs. Many homology modeling based methods use molecular dynamics
(MD) simulations to sample accessible conformational space, but these methods need to
expand their conformational sampling capability to capture the diversity of distinct
conformations observed for GPCRs. They are expected to work for only the most closely
related receptors (TM sequence similarity > 60%), e.g., predicting humBeta2 structure from
humBeta1 template, but not for predicting humBeta2 structure from humA2A template.
GEnSeMBLE (GPCR Ensemble of Structures in Membrane BiLayer Environment) [60] is
one such method that uses the homology-based model only as a starting structure but then
performs local but rigorous conformational sampling in the space specified by the three
TMHTOP helix orientation angles (θ,ϕ,η). It is a de novo structure prediction method that
implements a complete sampling of this space using a highly efficient but fast BiHelix
algorithm[61], that splits up a seven-helix bundle problem into many two-helix bundle
problems. The extent of sampling that may be necessary is pre-determined by the analysis of
sequence similarity and changes in TMHTOP parameters seen so far (Figure 6). An
application of this method is provided below to demonstrate that TMHTOP analysis need
not be done in isolation but can be coupled to structure prediction methods to estimate the
conformational space sampling that may be necessary, as such sampling can be
computationally prohibitive. Similar de novo effort is required to predict active
conformations starting from the inactive conformations as homology modeling and/or MD
simulations cannot be expected to sample the conformational changes necessary for
activation, especially because the active conformations have higher energy than the inactive
conformations for the apo receptors.
To demonstration this structure prediction guidance provided by TMHTOP analysis, we
predicted the structure of humA2A receptor starting with the humBeta2 receptor as a
template. These sequences share a similarity of 50% in their TM regions, which is high by
soluble proteins’ standards and gives confidence in homology models for those soluble
proteins. This will allow for the direct comparison of homology based models and those
predicted by de novo methods. The starting structure for humA2A was built by placing
crystal humA2A TM helices in the humBeta2 template. Using original crystal helices allows
one to remove any noise in the procedure coming from the different TM helix shapes
(between humA2A and humBeta2) and provides a clearer demonstration of the comparison
between homology and de novo models. So, the starting structure can be considered the
homology structure and has a CαRMSD of 2.1Å relative to the humA2A crystal TM bundle.
The above mentioned three orientation angles will be used to sample the conformational
space of ±10° in θ (with Δθ=10°), ±30° in ϕ (with Δϕ=15°), and ±30° in η (with Δη=15°)
(with indications from Figure 6 for changes in TMHTOP parameters) using this homology
model as a starting strucure. Even this limited space corresponds to ~13 trillion TM bundle
conformations. The above mentioned GEnSeMBLE method of de novo structure prediction
that samples θ,ϕ,η conformational space (described above) was applied to this TM bundle to
see if the procedure can identify the native humA2A crystal conformation starting from the
humBeta2 template. After the sampling procedure, the lowest energy conformation had an
improved CαRMSD of 1.4Å relative to the crystal structure. Figure 7A compares this and
the starting structure with the crystal structure.
The three receptor structures shown in Figure 7A were used in a docking exercise using
MSCDock [62] to predict the binding site for humA2A ligand ZM241385. The predicted
binding site of this ligand for the de novo predicted receptor structure (Figure 7C) shows
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much better agreement with the co-crystal pose (Figure 7D). It forms a strong hydrogen
bond with N253(TM6), consistent with the experimental structure. The docked ligand in the
homology structure takes a very different pose, and does not form any hydrogen bond with
N253(TM6). This shows that a homology model 2.1Å away in CαRMSD from the crystal
structure was not accurate enough to predict the ligand binding site in the absence of any
other experimental data (e.g. mutagenesis).
3. Conclusions
The number of experimental 7TMR structures has exploded since 2007, and now the
structures not only cover a large sequence space for class A 7TMRs, but for many receptors
more than one functionally distinct conformation. These receptors are characterized by a
single-fold of 7 TM helices crossing the membrane seven times. We have presented an
intuitive geometric set of TMHTOP helix orientation parameters that can quantify the
topologies of all these single-fold structures using a standard set of definitions, which will
allow for direct visual and quantitative comparison of the structures and conformations in
terms of these parameters. As more 7TMR structures are solved, the comparison of these
parameters across all available experimental structures will provide a quantitative view of
the differences in topology exhibited by these critical receptors. These topological
differences coupled to sequence homology information can guide the application of
homology-based or de novo structure prediction methods and make the resulting structures
more reliable. The same orientation parameters can describe the structural changes
underlying activation of these receptors and shed critical light on the activation mechanisms
to develop and test novel hypotheses of receptor function. Given the diversity of roles
played by 7TMRs, the availability of these topological comparisons and associated
functional hypotheses provides a common language and broad strategy to investigate the
fundamental pleiotropic nature of 7TMRs.
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Figure 1.
Functional and thermodynamic view of 7TMR conformational ensembles.
Abrol et al. Page 14
Methods. Author manuscript; available in PMC 2012 December 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Coordinates specifying the orientation of a TM helix in a membrane.
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Figure 3.
Deviations in TM helix topology parameters for inactive conformations of all (green) and
only aminergic (red) crystallized 7TMRs. A. Deviation in R vs η; B. Deviation in θ vs η; C.
Deviation in ϕ vs η; D. Deviation of R vs ϕ; E. Deviation of θ vs ϕ; F. Deviation of R vs θ.
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Figure 4.
Deviations in TM helix topology parameters for active conformations of rhodopsin (green),
β2 (green) and A2A (red) receptors. Description of panels A through F same as in Figure 3.
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Figure 5.
Deviations in TM helix topology parameters for dark state vs metaII state of rhodopsin
(green), inactive β2 conformation vs Gs bound β2 conformation (green), and inactive A2A
conformation vs agonist bound active A2A conformation (red). Description of panels A
through F same as in Figure 3.
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Figure 6.
Correlation of maximum deviation (over all TMs) in orientation parameters with sequence
identity (red) and similarity (green): A. Helix position R deviation; B. Helix tilt angle θ
deviation; C. Helix sweep angle ϕ deviation; D. Helix rotation angle η deviation.
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Figure 7.
A. Comparison of A2A homology structure (red) based on humBeta2 template and de novo
predicted structure (blue) with the crystal structure (green); B. Ligand binding site for
homology structure; C. Ligand binding site for de novo predicted structure; D. Ligand
binding site in the co-crystal [17].
Abrol et al. Page 20
Methods. Author manuscript; available in PMC 2012 December 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Abrol et al. Page 21
Ta
bl
e 
1
TM
 H
el
ix
 o
rie
nt
at
io
n 
pa
ra
m
et
er
s a
nd
 η 
re
si
du
e 
fo
r t
he
 fi
rs
t h
um
an
 β2
 a
dr
en
er
gi
c 
re
ce
pt
or
 st
ru
ct
ur
e 
[1
6]
.
hB
et
a2
A
R
 (P
D
B
id
: 2
rh
1)
 +
 p
ar
tia
l i
nv
er
se
 a
go
ni
st
 c
ar
az
ol
ol
 (2
.4
 A
)
T
M
x
y
H
PC
(h
)
θ
ϕ
η
ηR
E
S
1
19
.8
0
−3
.98
43
.6
1
36
.2
3
13
2.
58
19
6.
34
N
51
2
9.
86
0.
00
81
.4
5
28
.6
0
34
0.
28
27
5.
87
D
79
3
0.
00
0.
00
11
7.
52
28
.8
0
21
7.
12
31
0.
30
D
11
3
4
−5
.03
6.
30
16
0.
22
7.
43
26
7.
40
34
7.
71
W
15
8
5
−8
.54
−9
.09
20
9.
51
15
.7
0
27
5.
27
85
.3
5
P
21
1
6
−0
.38
−1
3.8
2
28
5.
70
13
.1
5
20
8.
53
31
8.
93
P
28
8
7
9.
82
−1
0.5
5
31
6.
83
15
.3
1
57
.0
0
68
.1
8
P
32
3
Methods. Author manuscript; available in PMC 2012 December 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Abrol et al. Page 22
Ta
bl
e 
2
Se
qu
en
ce
 c
om
pa
ris
on
 a
cr
os
s 5
 7
TM
R
 se
qu
en
ce
s, 
w
ith
 fi
rs
t n
um
be
r f
or
 th
e 
w
ho
le
 se
qu
en
ce
 a
nd
 th
e 
se
co
nd
 n
um
be
r f
or
 a
ll 
TM
s:
 A
. S
eq
ue
nc
e 
Id
en
tit
y;
 B
.
Se
qu
en
ce
 S
im
ila
rit
y.
A
%
 S
eq
ue
nc
e 
Si
m
ila
ri
ty
 (F
ul
l_
Se
q 
/ O
nl
y_
T
M
s)
bo
vR
ho
d
hu
m
B
et
a2
tu
rB
et
a1
hu
m
A
2A
sq
uR
ho
d
hu
m
D
3
hu
m
C
X
C
R
4
hu
m
H
1
bo
vR
ho
d
10
0/
10
0
14
/2
0
14
/2
2
14
/2
5
21
/3
2
16
/2
8
15
/1
9
10
/1
9
hu
m
B
et
a2
14
/2
0
10
0/
10
0
43
/6
9
21
/3
3
17
/2
8
22
/4
0
17
/2
4
18
/3
7
tu
rB
et
a1
14
/2
2
43
/6
9
10
0/
10
0
22
/3
8
16
/2
7
21
/4
4
15
/2
2
17
/3
8
hu
m
A
2A
14
/2
5
21
/3
3
22
/3
8
10
0/
10
0
18
/2
3
17
/3
4
13
/2
4
16
/3
5
sq
uR
ho
d
21
/3
2
17
/2
8
16
/2
7
18
/2
3
10
0/
10
0
12
/2
0
13
/2
2
11
/2
6
hu
m
D
3
16
/2
8
22
/4
0
21
/4
4
17
/3
4
12
/2
0
10
0/
10
0
16
/2
9
22
/3
8
hu
m
C
X
C
R
4
15
/1
9
17
/2
4
15
/2
2
13
/2
4
13
/2
2
16
/2
9
10
0/
10
0
13
/2
4
hu
m
H
1
10
/1
9
18
/3
7
17
/3
8
16
/3
5
11
/2
6
22
/3
8
13
/2
4
10
0/
10
0
B
%
 S
eq
ue
nc
e 
Id
en
tit
y 
(F
ul
l_
Se
q 
/ O
nl
y_
TM
s)
bo
vR
ho
d
hu
m
B
et
a2
tu
rB
et
a1
hu
m
A
2A
sq
uR
ho
d
hu
m
D
3
hu
m
C
X
C
R
4
hu
m
H
1
bo
vR
ho
d
10
0/
10
0
31
/4
3
26
/4
2
27
/4
7
38
/5
9
30
/4
9
31
/3
5
24
/4
3
hu
m
B
et
a2
31
/4
3
10
0/
10
0
55
/8
3
33
/5
0
33
/5
0
35
/6
3
31
/4
4
31
/6
2
tu
rB
et
a1
26
/4
2
55
/8
3
10
0/
10
0
34
/5
4
31
/5
0
31
/6
4
28
/4
5
29
/6
2
hu
m
A
2A
27
/4
7
33
/5
0
34
/5
4
10
0/
10
0
32
/4
6
27
/5
3
26
/4
4
24
/5
2
sq
uR
ho
d
38
/5
9
33
/5
0
31
/5
0
32
/4
6
10
0/
10
0
25
/4
4
27
/4
5
21
/5
1
hu
m
D
3
30
/4
9
35
/6
3
31
/6
4
27
/5
3
25
/4
4
10
0/
10
0
27
/4
4
36
/6
1
hu
m
C
X
C
R
4
31
/3
5
31
/4
4
28
/4
5
26
/4
4
27
/4
5
27
/4
4
10
0/
10
0
23
/4
3
hu
m
H
1
24
/4
3
31
/6
2
29
/6
2
24
/5
2
21
/5
1
36
/6
1
23
/4
3
10
0/
10
0
Methods. Author manuscript; available in PMC 2012 December 17.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Abrol et al. Page 23
Table 3
Pearson and Spearman Correlation Coefficients for maximum deviation in TMHOP variables and TM Identity
or TM Similarity across all pairs of 7TMRs considered in this work.
Correlation
Coefficients
Pearson Spearman
TM Identity TM Similarity TM Identity TM Similarity
max[ΔR] −0.53 −0.51 −0.46 −0.43
max[Δθ] −0.11 −0.19 −0.07 −0.11
max[Δϕ] −0.37 −0.44 −0.31 −0.37
max[Δη] −0.69 −0.69 −0.72 −0.72
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